Verition Fund Management
OACC

Verition Fund Management’s Oaktree Acquisition Corp III Life Sciences OACC Stock Holding History

Verition Fund Management’s Portfolio OACC Stock Details OACC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.24M Sell
305,048
-4,692
-2% -$50K 0.02% 766
2025
Q4 		$3.29M Buy
309,740
+148,000
+92% +$1.57M 0.01% 1181
2025
Q3 		$1.69M Buy
161,740
+10,117
+7% +$106K 0.01% 2116
2025
Q2 		$1.59M Buy
151,623
+4,774
+3% +$49.5K 0.01% 2119
2025
Q1 		$1.5M Sell
146,849
-53,151
-27% -$533K 0.01% 1793
2024
Q4 		$2M Buy
+200,000
New +$2M 0.01% 1554

Other funds holding OACC

AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $386M AUM 45.42% 1-Year Est. Return
FBCM
Fort Baker Capital Management Larkspur, California $1.27B AUM 25.46% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BGIM
Boussard & Gavaudan Investment Management London, United Kingdom $1.06B AUM 4.58% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return

Verition Fund Management's OACC Position: Q1 2026 in Review

Verition Fund Management reduced its Oaktree Acquisition Corp III Life Sciences (OACC) stake by 1.5% in Q1 2026, selling an estimated $50K and leaving 305,048 shares worth $3.24M. The position accounts for 0.02% of the portfolio, ranked #766.

Verition Fund Management first reported a position in OACC in Q4 2024 and has held it in 6 quarters since. The position peaked at $3.29M in Q4 2025. 51 funds tracked by Wall St. Rank hold OACC as of Q1 2026.

  • Verition Fund Management held 305,048 shares of Oaktree Acquisition Corp III Life Sciences worth $3.24M as of Q1 2026.
  • Verition Fund Management sold 4,692 Oaktree Acquisition Corp III Life Sciences shares in Q1 2026, an estimated $50K.
  • Oaktree Acquisition Corp III Life Sciences made up 0.02% of Verition Fund Management's portfolio in Q1 2026, its #766 holding.
  • Verition Fund Management first reported a position in Oaktree Acquisition Corp III Life Sciences in Q4 2024 and has held it in 6 quarters since.
  • Verition Fund Management's Oaktree Acquisition Corp III Life Sciences position peaked at $3.29M in Q4 2025.
  • 51 funds tracked by Wall St. Rank held Oaktree Acquisition Corp III Life Sciences as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.